RT Journal Article
SR Electronic
T1 How effective are face coverings in reducing transmission of COVID-19?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.01.20241992
DO 10.1101/2020.12.01.20241992
A1 Robinson, Joshua F.
A1 de Anda, Ioatzin Rios
A1 Moore, Fergus J.
A1 Gregson, Florence K. A.
A1 Reid, Jonathan P.
A1 Husain, Lewis
A1 Sear, Richard P.
A1 Royall, C. Patrick
YR 2020
UL http://medrxiv.org/content/early/2020/12/03/2020.12.01.20241992.abstract
AB In the COVID–19 pandemic, among the more controversial issues is the use of face coverings. To address this we show that the underlying physics ensures particles with diameters ≳1 µm are efficiently filtered out by a simple cotton or surgical mask. For particles in the submicron range the efficiency depends on the material properties of the masks, though generally the filtration efficiency in this regime varies between 30 to 60 % and multi-layered cotton masks are expected to be comparable to surgical masks.Respiratory droplets are conventionally divided into coarse droplets (≳5–10 µm) responsible for droplet transmission and aerosols (≳ 5–10 µm) responsible for airborne transmission. Masks are thus expected to be highly effective at preventing droplet transmission, with their effectiveness limited only by the mask fit, compliance and appropriate usage. By contrast, knowledge of the size distribution of bioaerosols and the likelihood that they contain virus is essential to understanding their effectiveness in preventing airborne transmission. We argue from literature data on SARS-CoV-2 viral loads that the finest aerosols (≳ 1 µm) are unlikely to contain even a single virion in the majority of cases; we thus expect masks to be effective at reducing the risk of airborne transmission in most settings.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll underlying code is available at: https://github.com/tranqui/maskflow